PDGFRA and central nervous system cancer: Our results were consistent with the clinical observations that, single inhibition of PDGFRA by dasatinib had failed to improve the clinical outcomes of glioma, even in glioma patients with PDGFRA amplifications or over‐expressions.46, 47